Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$124.7M
6 rounds on record
Latest round
$22.1M
Venture round · Jul 2026 · 2 mo ago
Team
51-200
employees, estimated range
Hiring now
4
open roles
Grants
$3.9M
3 grants · CORDIS
Backers
3
Kurma Partners, Vi Partners
The money's age
Fresh money
2 months since the last round · hiring slowed
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2026 | $22.1M | — | xeltis.com |
| Venture round | Dec 2025 | $54M | — | xeltis.com |
| Grant | Dec 2022 | $2.7M | — | CORDIS |
| Grant | Jan 2021 | $691k | — | CORDIS |
| Series C | Nov 2017 | $48.6M | — | medindia.net |
| Grant | Nov 2017 | $479k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Kurma Partners 
Vi Partners 
Ysios Capital Similar startupsby what they do, their industry and backers
Capstan Medical develops robotically delivered heart valve implants for minimally invasive structural heart repair. Its system combines a…
Arpelos designs multivalent medicines with transformative outcomes.
Reimagining valve technology About We engineer and manufacture the world's most revolutionary valves and regulators.Leveraging our…
Thoraguard: A transformative digital drainage system for cardiothoracic surgery.
ICHOR Vascular develops next-generation clot removal technology that improves safety, speed, and outcomes in vascular intervention.
Therapeutic Ultrasound-Based Solution for Vascular Care. cardiovascular disease is VTE. ¹.
News
Xeltis raises an additional €20.5m of funding to advance aXess toward FDA approval and US commercial launch
New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in 2025 and supports Xeltis' next phase of
Read more
Report
Xeltis makes first commercial implant of aXess, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess, bringing it into routine clinical practiceBuilds on CE mark approval in record time, underpi...
Read more
Report
Xeltis makes first commercial implant of aXess, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data Introduces a first-of-its-kind living vascular access solution for pat
Read more
Report
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess, its vascular access device for hemodialysis
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice 50% of target enrollment reached across 20 sites in the United States EINDHOVEN,
Read more
Report
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess demonstrating the transformative potential in hemodialysis treatment
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1
Read more
Report
Pro access
Upgrade to see all 20 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Tech stack
Technologies named in job postings at Xeltis over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Developer tools
SolidWorks
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
41/100
Stable
Open positions
4
1 opened / 1 closed in 30 days
Median time-to-fill
14 days
faster than 59% of the market
ATS activity
Every ~3 days
09/27/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Industrial Engineering
40% ▲
Operations
20% ▼
Customer Success
20% ▼
Field & Service
20% ▼
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Eindhoven
Eindhoven
Netherlands
Plant / site
4 open roles 5 posted in 90 days 50-200 est. staff
hires for Operations, Customer Success, Field & Service
De Lismortel 31
Financials
Total raised
$128.6M
Latest round
Venture - Series Unknown
Funding rounds
6